Long-Term Treatment of Venous Thromboembolic Disease

Martin H. Prins; Barbara A. Hutten; Maria M.W. Koopman; Harry R. Büller

doi:10.1055/s-0037-1615928

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 82(02): 892-898
DOI: 10.1055/s-0037-1615928

Research Article

Schattauer GmbH

Long-Term Treatment of Venous Thromboembolic Disease

Martin H. Prins

¹Department of Clinical Epidemiology & Biostatistics, Amsterdam, THE NETHERLANDS

,

Barbara A. Hutten

¹Department of Clinical Epidemiology & Biostatistics, Amsterdam, THE NETHERLANDS

,

Maria M.W. Koopman

²Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, THE NETHERLANDS

,

Harry R. Büller

²Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, THE NETHERLANDS

› Author Affiliations

Abstract

Introduction

After an initial 5- to 10-day course of treatment with either unfractionated or low molecular weight heparin, secondary prophylaxis is usually prescribed to patients with venous thromboembolic disease for a variable period of time. The primary aim of both initial and secondary treatment is to prevent recurrent thrombotic events, including deep vein thrombosis and fatal pulmonary embolism. This objective has to be achieved at a minimal risk of bleeding. There is general consensus that the initial treatment should be with low molecular weight or unfractionated heparin. For secondary prophylaxis, however, there are currently several options. Among these are continued unfractionated heparin or low molecular weight heparin and oral vitamin K-antagonists. In addition, compression stockings and caval vein filters are available.

In this chapter, we will first examine the available evidence for each of these options, then discuss the results of randomized trials that have studied the duration of secondary prophylaxis. Finally, we will attempt to synthesize this information using decision analytic techniques.

Full Text

References

References
1 Barrit DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; I: 1309-12.
2 Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985; II: 515-18.
3 Hull RD, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, McLaughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94
4 Hull RD, Hirsch J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-81.
5 Hull RD, Delmore T, Carter C, Hirsch J, Genton E, Gent M, Turpie G, McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
6 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-97.
7 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost 1994; 71: 7-11.
8 Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simmoneau G. A clinical trial of vena caval vein filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-415.
9 Brandjes DP, Büller HR, Heijboer H, Huisman MV, De Rijk M, Jagt H, Ten Cate JW. A randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349 (9054) 759-62.
10 Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336 (06) 393-8.
11 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332 (25) 1661-5.
12 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74 (02) 606-11.
13 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340 (8824) 873-6.
14 Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. A comparison of 3 and 6 weeks’ anticoagulation in the treatment of venous thromboembolism. Clinical & Laboratory Haematology 1987; 9 (01) 17-21.
15 Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. A randomized study. Acta Med Scand 1985; 217 (05) 547-52.
16 Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 179-84.
17 O’Sullivan EF. Duration of anticoagulant therapy in venous thrombo-embolism. Med J Aust 1972; 2: 1104-7.
18 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
19 Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996; 76 (01) 12-6
20 Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
21 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. on behalf of the ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) Study Group. Bleeding complications of oral anticoagulant treatment: An inception cohort, prospective, collaborative study (ISCOAT). Lancet 1996; 348: 423-28.
22 Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (Factor V Leiden). N Engl J Med 1997; 336: 399-403.
23 Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with factor V Leiden mutation in a United Kingdom population. Thromb Haemostas 1996; 77: 440-3.
24 Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of bleeding during anticoagulant treatment for venous thromboembolism. Arch Int Med. In press.
25 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Büller HR. The incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to malignancy and achieved INR. Submitted.
26 Van den Besselaar AMHP, Breddin K, Lutze G, Parker-Williams J, Taborski U, Vogel G, Trichler W, Zerback R, Leinberger L. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul Fibrinol 1995; 6: 726-732.
27 Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 1998; 3: 67-73.
28 Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-7.
29 Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A. among others Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemostas 1999; 81: 26-31.
30 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med 1999; 340 (12) 91-7.